Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells
CD: cluster of differentiation YF: yellow fever
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
60
STAMARIL, powder and solvent for suspension for injection in pre-filled syringe. After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU. Powder and solvent for suspension for injection. Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.
Aarhus University Hospital
Aarhus, Denmark
Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 21(+/-3) days after vaccination with YF-17D
Measured by flow cytometry
Time frame: 21(+/-3) days
Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 100 (+/- 40) days after vaccination with YF-17D
Measured by flow cytometry
Time frame: 100 (+/- 40) days
% of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing
Measured by polymerase chain reaction
Time frame: 21(+/-3) days
% of patients with novel yellow fever vaccine epitopes according to HLA-type defining optimal timepoint for T cell licensing
Measured by polymerase chain reaction
Time frame: 100 (+/- 40) days
Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells
Measured by ex vivo killing assay
Time frame: 21(+/-3) days
Proportion of target cells killed ex vivo from in vivo generated YF-specific CD8+ T cells
Measured by ex vivo killing assay
Time frame: 100 (+/- 40) days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.